Brief: Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation For Elx-02 For The Treatment Of Cystic Fibrosis
04/08/2020 12:38
Aug 4 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS RECEIVES U.S. ORPHAN DRUG
DESIGNATION FOR
ELX-02 FOR THE TREATMENT OF CYSTIC FIBROSIS
Source text for Eikon: ID:nGNXpjjxC
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome